Skip to content

Early Supplementation of Enteral Microlipid With and Without Fish Oil in Premature Infants With Enterostomies

Early Supplementation of Enteral Microlipid With and Without Fish Oil in Premature Infants With Enterostomies

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01674478
Acronym
EMLFO-2
Enrollment
18
Registered
2012-08-28
Start date
2012-10-31
Completion date
2015-03-17
Last updated
2018-12-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prematurity, Intestine Perforation, Necrotizing Enterocolitis (NEC), Short Bowel Syndrome (SBS)

Keywords

NEC, SBS, enterostomy, fish oil, Microlipid, Intralipid,, enteral fat

Brief summary

Necrotizing enterocolitis (NEC) and spontaneous intestinal perforation (SIP) are common devastating gastrointestinal diseases in premature infants. These infants often need surgical intervention to remove the dead bowel and create temporary enterostomies, resulting in short bowel syndrome (SBS), a malabsorption state due to insufficient bowel length or dysfunction to digest and absorb nutrients adequately. These infants are often nourished primarily with parental nutrition (PN) which can lead to many complications including PN-associated liver disease. However, with enteral feeding, the remaining bowel can adapt somewhat to the shortened state, reducing the need for PN. Enteral fats appear to be the most trophic macronutrients with the long chain polyunsaturated fatty acids (LCPUFA) being the most beneficial in promoting bowel adaptation. Fish oil (FO), a main source of n-3 LCPUFA, has been shown to promote bowel adaptation. Microlipid (ML) primarily contains n-6 PUFA and has been found to decrease ostomy output and increase weight gain in some SBS infants. WThe investigators will soon have completed a randomized clinical trial (EMLFO trial) (WFUHS IRB00011501, NCT01306838) entitled Early Supplementation of Enteral Lipid with Combination of Microlipid and Fish Oil in Infants with Enterostomies. The preliminary data suggest that (a) by supplementing enteral ML/FO, we were able to decrease the use of IL; (b) premature infants in the treatment group who received ML/FO achieved higher enteral calorie (% of total calorie) intake before reanastomosis and better weight gain (g/day) after reanastomosis than those who received routine care in control group; and (c) the direct bilirubin level before reanastomosis tended to be lower in the treatment group than the control group although the difference was not statistically significant. Because the intervention consisted of both an increase in enteral fat intake as well as a specific type of fat intake (i.e. FO), it is unclear whether improved outcomes in the ML/FO group are attributable to FO's anti-inflammatory effects or the increased fat intake. Therefore, the investigators have designed a next randomized clinical trial to compare ML alone versus ML plus FO. We hypothesize that as compared to ML alone, ML plus FO will result in decreased systemic inflammation, as indicated by blood levels of inflammation-related proteins and indicators of oxidative stress.

Detailed description

In comparison to EMLFO trial, the EMLFO-2 study will modify the eligibility criteria to only enroll the infants who have birthweight equal to or less than 1250 g with a jejunostomy or ileostomy as the result of surgical treatment for small intestine perforation or NEC in order to increase the homogeneity of patient population.

Interventions

DIETARY_SUPPLEMENTMicrolipid with fish oil

Fish oil will start with initial feeding after ostomy placement and Microlipid will start once infant tolerating enteral feeds at 20 ml /kg/d while weaning the Intralipid, which both will be continued until reanastomosis.

DIETARY_SUPPLEMENTMicrolipid

A small amount (ml) of Microlipid to match the amount of fish oil in ML/FO group will start with initial feeding after ostomy placement and Microlipid will start once infant tolerating enteral feeds at 20 ml /kg/d while weaning the Intralipid, which will be continued until reanastomosis.

Sponsors

Wake Forest University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
1 Days to 2 Months
Healthy volunteers
No

Inclusion criteria

1. infants (age range: newborn to ≤ 2-month-old) whose birth weight are ≤ 1250g; 2. who are admitted to BCH NICU for surgical intervention for NEC or small intestine perforation and then to have a jejunostomy or ileostomy; 3. who are expected to need full or partial PN for at least 21days from the day of ostomy placement; and 4. who have received enteral feedings ≤ 4 days since ostomy placement.

Exclusion criteria

1. infant with birth weight \> 1250g; 2. infant with colostomy; 3. infants with enterostomy but * unable to obtain written informed consent from parent; * presence of congenital liver, renal, or metabolic diseases or syndromes or perinatal asphyxia; * ostomy caused by surgical treatment for a condition other than NEC or small intestine perforation; and * unable to initiate enteral feeding for more than 28 days since ostomy placement.

Design outcomes

Primary

MeasureTime frameDescription
The Serum Biomarkers of Inflammatory Cytokines2 years and 5 monthsCompare the serum biomarkers of inflammatory cytokines of the infants receiving ML/FO to the infants only receiving ML between the initial feeding after placement of an ostomy and reanastomosis
The Serum Biomarkers of Oxidative Stress2 years and 5 monthsCompare the serum biomarkers of oxidative stress of the infants receiving ML/FO to the infants only receiving ML between the initial feeding after placement of an ostomy and reanastomosis

Secondary

MeasureTime frameDescription
The Average Enteral Calorie (Total Calorie) Intake Before Reanast2 years and 5 monthsTo compare the average enteral calorie (total calorie) intake of infants receiving ML/FO to the group only receiving ML between the initial feeding after placement of an ostomy and reanastomosis
The Average Weight Gain (g/Day) After Reanastomosis2 years and 5 monthsTo compare the the average weight gain (g/day) of infants receiving ML/FO to the infants only receiving ML after reanastomosis

Countries

United States

Participant flow

Participants by arm

ArmCount
Microlipid and Fish Oil Group
This group will be given early enteral lipid supplementation with Microlipid and fish oil. Microlipid and fish oil: Fish oil will start with initial feeding after ostomy placement and Microlipid will start once infant tolerating enteral feeds at 20 ml /kg/d while weaning the Intralipid, which both will be continued until reanastomosis.
9
Microlipid Group
This group will be given early enteral lipid supplementation only with Microlipid. Microlipid: A small amount (ml) of Microlipid to match the amount of fish oil in ML/FO group will start with initial feeding after ostomy placement and Microlipid will start once infant tolerating enteral feeds at 20 ml /kg/d while weaning the Intralipid, which will be continued until reanastomosis.
9
Total18

Baseline characteristics

CharacteristicMicrolipid and Fish Oil GroupMicrolipid GroupTotal
Age, Continuous26.3 weeks
STANDARD_DEVIATION 2
25.9 weeks
STANDARD_DEVIATION 2
26.1 weeks
STANDARD_DEVIATION 2
Sex: Female, Male
Female
4 Participants3 Participants7 Participants
Sex: Female, Male
Male
5 Participants6 Participants11 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 90 / 9
other
Total, other adverse events
0 / 90 / 9
serious
Total, serious adverse events
0 / 90 / 9

Outcome results

Primary

The Serum Biomarkers of Inflammatory Cytokines

Compare the serum biomarkers of inflammatory cytokines of the infants receiving ML/FO to the infants only receiving ML between the initial feeding after placement of an ostomy and reanastomosis

Time frame: 2 years and 5 months

Population: No data collected

Primary

The Serum Biomarkers of Oxidative Stress

Compare the serum biomarkers of oxidative stress of the infants receiving ML/FO to the infants only receiving ML between the initial feeding after placement of an ostomy and reanastomosis

Time frame: 2 years and 5 months

Population: No data collected

Secondary

The Average Enteral Calorie (Total Calorie) Intake Before Reanast

To compare the average enteral calorie (total calorie) intake of infants receiving ML/FO to the group only receiving ML between the initial feeding after placement of an ostomy and reanastomosis

Time frame: 2 years and 5 months

ArmMeasureValue (MEAN)Dispersion
Microlipid and Fish Oil GroupThe Average Enteral Calorie (Total Calorie) Intake Before Reanast52.1 kcal/kg/dayStandard Deviation 23.6
Microlipid GroupThe Average Enteral Calorie (Total Calorie) Intake Before Reanast56.7 kcal/kg/dayStandard Deviation 15.6
Secondary

The Average Weight Gain (g/Day) After Reanastomosis

To compare the the average weight gain (g/day) of infants receiving ML/FO to the infants only receiving ML after reanastomosis

Time frame: 2 years and 5 months

ArmMeasureValue (MEAN)Dispersion
Microlipid and Fish Oil GroupThe Average Weight Gain (g/Day) After Reanastomosis26.6 g/dStandard Deviation 8.5
Microlipid GroupThe Average Weight Gain (g/Day) After Reanastomosis20.9 g/dStandard Deviation 12.2

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026